These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 31678539)

  • 1. Inpatient Healthcare Resource Utilization, Costs, and Mortality in Adult Patients with Acute Graft-versus-Host Disease, Including Steroid-Refractory or High-Risk Disease, following Allogeneic Hematopoietic Cell Transplantation.
    Yu J; Judy JT; Parasuraman S; Sinha M; Weisdorf D
    Biol Blood Marrow Transplant; 2020 Mar; 26(3):600-605. PubMed ID: 31678539
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Healthcare resource utilization and costs associated with acute graft-versus-host disease following allogeneic hematopoietic cell transplantation.
    Yu J; Lal L; Anderson A; DuCharme M; Parasuraman S; Weisdorf D
    Support Care Cancer; 2020 Nov; 28(11):5491-5499. PubMed ID: 32172407
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Healthcare resource utilization and costs among patients with steroid-resistant chronic graft-versus-host disease in the United States: a retrospective claims database analysis.
    Yu J; Lal LS; Anderson A; DuCharme M; Parasuraman S; Weisdorf D
    Curr Med Res Opin; 2021 May; 37(5):755-759. PubMed ID: 33615925
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Healthcare Resource Utilization and Costs of Steroid-Associated Complications in Patients With Graft-Versus-Host Disease.
    Bell EJ; Yu J; Bhatt V; Bunner SH; Lal LS; Galvin J; Weisdorf D
    Transplant Cell Ther; 2022 Oct; 28(10):707.e1-707.e7. PubMed ID: 35483620
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Severity of Acute Graft-versus-Host Disease and Associated Healthcare Resource Utilization, Cost, and Outcomes.
    Farhadfar N; Leather HL; Wang S; Burton N; IrizarryGatell V; Itzler R; Salloum RG; Wingard JR
    Transplant Cell Ther; 2021 Dec; 27(12):1007.e1-1007.e8. PubMed ID: 34537422
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Economic burden of acute steroid-refractory graft-versus-host disease in commercially insured pediatric patients.
    Grabner M; Strati E; Sandman K; Forsythe A
    J Manag Care Spec Pharm; 2021 May; 27(5):607-614. PubMed ID: 33908282
    [No Abstract]   [Full Text] [Related]  

  • 7. Economic and Clinical Burden of Virus-Associated Hemorrhagic Cystitis in Patients Following Allogeneic Hematopoietic Stem Cell Transplantation in the United States.
    McGuirk J; Divine C; Moon SH; Chandak A; Zhang Z; Papanicolaou GA
    Transplant Cell Ther; 2021 Jun; 27(6):505.e1-505.e9. PubMed ID: 33775616
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mortality, length of stay and costs associated with acute graft-versus-host disease during hospitalization for allogeneic hematopoietic stem cell transplantation.
    Yu J; Parasuraman S; Shah A; Weisdorf D
    Curr Med Res Opin; 2019 Jun; 35(6):983-988. PubMed ID: 30461314
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disease progression, hospital readmissions, and clinical outcomes for patients with steroid-refractory acute graft-versus-host disease: A multicenter, retrospective study.
    Holtan SG; Yu J; Paranagama D; Tang J; Choe HK; Naim A; Joachim Deeg H; Galvin J
    Bone Marrow Transplant; 2022 Sep; 57(9):1399-1404. PubMed ID: 35739326
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Steroid-Sensitive, but Not Steroid-Dependent or Steroid-Resistant Acute Graft-versus-Host Disease, Results in Similar Infection Risk as No Graft-versus-Host Disease following Allogeneic Hematopoietic Cell Transplantation.
    Young JH; El Jurdi N; Rayes A; MacMillan ML; Holtan SG; Cao Q; Witte J; Arora M; Weisdorf DJ
    Transplant Cell Ther; 2022 Aug; 28(8):509.e1-509.e11. PubMed ID: 35577324
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low-Dose Antithymocyte Globulin for Graft-versus-Host-Disease Prophylaxis in Matched Unrelated Allogeneic Hematopoietic Stem Cell Transplantation.
    Bryant A; Mallick R; Huebsch L; Allan D; Atkins H; Anstee G; Sabloff M; Scrivens N; Maze D; Bredeson C; Kekre N
    Biol Blood Marrow Transplant; 2017 Dec; 23(12):2096-2101. PubMed ID: 28821454
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epidemiology and Treatment of Chronic Graft-versus-Host Disease Post-Allogeneic Hematopoietic Cell Transplantation: A US Claims Analysis.
    Bachier CR; Aggarwal SK; Hennegan K; Milgroom A; Francis K; Dehipawala S; Rotta M
    Transplant Cell Ther; 2021 Jun; 27(6):504.e1-504.e6. PubMed ID: 34158154
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Prospective Study of Alemtuzumab as a Second-Line Agent for Steroid-Refractory Acute Graft-versus-Host Disease in Pediatric and Young Adult Allogeneic Hematopoietic Stem Cell Transplantation.
    Khandelwal P; Emoto C; Fukuda T; Vinks AA; Neumeier L; Dandoy CE; El-Bietar J; Chandra S; Davies SM; Bleesing JJ; Jordan MB; Mehta PA; Jodele S; Grimley MS; Kumar A; Myers KC; Marsh RA
    Biol Blood Marrow Transplant; 2016 Dec; 22(12):2220-2225. PubMed ID: 27664325
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased Health Care Utilization and Costs during Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia and Myelodysplastic Syndromes in Adolescents and Young Adults Compared with Children: A Multicenter Study.
    Rangarajan HG; Smith LC; Stanek JR; Hall M; Abu-Arja R; Auletta JJ; O'Brien SH
    Biol Blood Marrow Transplant; 2019 May; 25(5):1031-1038. PubMed ID: 30625391
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical and Economic Burden of Multiple Double-Stranded DNA Viral Infections after Allogeneic Hematopoietic Cell Transplantation.
    Hill JA; Moon SH; Chandak A; Zhang Z; Boeckh M; Maziarz RT
    Transplant Cell Ther; 2022 Sep; 28(9):619.e1-619.e8. PubMed ID: 35764288
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of Preemptive Therapy for Cytomegalovirus on Hospitalizations and Cost after Hematopoietic Stem Cell Transplantation.
    Fang J; Su Y; Zavras PD; Raval AD; Tang Y; Perales MA; Giralt S; Stern A; Papanicolaou GA
    Biol Blood Marrow Transplant; 2020 Oct; 26(10):1937-1947. PubMed ID: 32640313
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes of Reduced-Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation Performed in the Inpatient versus Outpatient Setting.
    Guru Murthy GS; Hari PN; Szabo A; Pasquini M; Narra R; Khan M; Abedin S; Chhabra S; Dhakal B; D'Souza A; Drobyski WR; Rizzo JD; Runaas L; Shah NN; Shaw B; Saber W; Fenske T; Hamadani M
    Biol Blood Marrow Transplant; 2019 Apr; 25(4):827-833. PubMed ID: 30572109
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disease progression, treatments, hospitalization, and clinical outcomes in acute GVHD: a multicenter chart review.
    Holtan SG; Yu J; Choe HK; Paranagama D; Tang J; Naim A; Galvin J; Joachim Deeg H
    Bone Marrow Transplant; 2022 Oct; 57(10):1581-1585. PubMed ID: 35908108
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytomegalovirus in Allogeneic Hematopoietic Transplantation: Impact on Costs and Clinical Outcomes Using a Preemptive Strategy.
    Saullo JL; Li Y; Messina JA; Thompson J; Dalton T; Giri VK; Reed SD; Miller R; Horwitz ME; Alexander BD; Sung AD
    Biol Blood Marrow Transplant; 2020 Mar; 26(3):568-580. PubMed ID: 31712193
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.